NEW YORK (Reuters Health) - A new study ties advertising for breast cancer drugs known as aromatase inhibitors to a slight increase in the total number of prescriptions for those medications. But the extra prescriptions were limited to women with a medical reason for taking those drugs. The ads didn't seem to increase the inappropriate use of aromatase inhibitors, which include letrozole (marketed as Femara) and anastrozole (Arimidex). ... Click here to read the rest
No comments:
Post a Comment